CDI Laboratories

Executive Summary

CDI Laboratories is a privately held biotechnology company based in Baltimore, Maryland, that has operated as a contract research organization (CRO) since 1990. The company specializes in proteomics services, particularly autoantibody profiling, biomarker discovery, and target identification, leveraging proprietary high-throughput protein microarray and PhIP-Seq technologies. Its platforms support research in autoimmune diseases, cancer, neurological disorders, and infectious diseases. Despite a long operating history, CDI Laboratories remains small-scale with no disclosed funding rounds or revenue figures, focusing on serving academic and pharmaceutical clients through fee-for-service projects. The company's expertise in autoantibody profiling positions it well for growth in the expanding autoimmune and biomarker discovery markets, but its private status and lack of publicly available financials limit visibility. CDI Laboratories' ability to secure large partnerships or contracts will be critical to scaling its operations and achieving commercial success.

Upcoming Catalysts (preview)

• Q4 2026Major pharma partnership for autoimmune biomarker discovery30% success
• Q2 2026Launch of expanded PhIP-Seq service for infectious disease monitoring60% success
• Q3 2026Grant award from NIH or other federal agency for technology development40% success